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Background: Revascularization with carotid stent (CAS) is considered the therapeutic alternative to endarterectomy
(CEA). However, its role compared to CEA remains questioned, mainly due of the heterogeneity of long-term
results. The objective of this study was to report the efficacy and durability of CAS in terms of stroke prevention
in a “real world experience”.
Method: This was a single-center retrospective analysis of 344 patients treated with CAS between January 2001
and December 2015.
The primary outcome of the trial was stroke, myocardial infarction, or death during a periprocedural period or
any stroke event over a 15-year follow-up. The secondary aim was to identify risk factors for 30-day complications,
long-term neurological complications, and intra-stent restenosis.
Results: The primary composite end point (any stroke, myocardial infarction, or death during the periprocedural
period) was 2.3%. The use of an EPD was protective against major complications.
Long-term follow-up was achieved in 294 patients (85,5%) with a median of 50 months (range 0-155 months).
Fifty-six (16,3%) died within this period, most commonly of nonvascular causes (4 patients had stroke-related
deaths). During the follow-up period, 8 strokes and 3 TIAs were diagnosed (3.2%).
ISR determined by sequential ultrasound was assessed in 4.4% of the patients and remained asymptomatic in all
but 2 patients (0.6%). All patients with restenosis underwent revascularization with balloon angioplasty.
Conclusion: The long-term follow-up results of our study validate CAS as a safe and durable procedure with
which to prevent ipsilateral stroke, with an acceptable rate of restenosis, recurrence and mortality.
Keywords: Neurointervention, Endovascular treatment, Carotid stenting, Revascularization, Carotid artery, Carotid
artery stenosis, Stroke, Long-term follow-upBackground
Cerebrovascular disease is an increasing global health
problem, responsible for 10% of deaths, worldwide
(Dorn et al., 2012). Carotid artery stenosis due to athero-
sclerotic disease is liable for approximately 20–30% of
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of recurrence (Coutts et al., 2008).
The American Heart Association/American Stroke
Association (AHA/ASA) (Kernan et al., 2014) considers
revascularization with stent to be a therapeutic alterna-
tive to surgery to prevent stroke, in select patients with
symptomatic carotid artery stenosis, although in many
centers surgery is still considered as the gold standard.
While this recommendation is supported by multiple
large randomized clinical trials, including CREST
(Bonati et al., 2015; Brott et al., 2016), we currently lack
long-term outcome data for CAS procedures. Further,is distributed under the terms of the Creative Commons Attribution 4.0
rg/licenses/by/4.0/), which permits unrestricted use, distribution, and
e appropriate credit to the original author(s) and the source, provide a link to
changes were made.
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plaque, which can result in restenosis and potentially
new stroke events. With an aging population and an
increasing life expectancy, long-term outcomes following
CAS are now needed to guide treatment appropriately.
The objective of this study was to report the efficacy
and durability of CAS in terms of stroke prevention. The
primary outcome of the trial was stroke, myocardial
infarction (MI), or death during a periprocedural period
(30 days after treatment), or any stroke event over a
15-year follow-up. The secondary aim was to identify
risk factors for 30-day complications, long-term neuro-
logical complications, and intra-stent restenosis (ISR).
Methods
This paper has been approved by the Ethics Committee
in our Hospital.
Patients
An observational retrospective study was performed using
material retrieved from a database describing a
single-center patient cohort. The study included 344
patients treated with CAS between January 2001 and
December 2015. All patients had carotid artery stenosis
documented by duplex ultrasound (toshiba aplio 300) and
confirmed by angiography. In those cases in which the
diagnosis was doubtful or unreliable, CT-angiography
(36,3%) or MRI-angiography (45,3%) was performed.
Inclusion criteria were: age > 18 years, with no upper
limit; symptomatic stenosis > 50%; asymptomatic sten-
osis > 60%, with more than one risk factor for future
embolism (i.e. progressive carotid stenosis, silent stroke
documented by neuroimaging, contralateral carotid
occlusion with high-risk carotid plaque, or microemboli
detected by transcranial duplex ultrasound).
Exclusion criteria included: life expectancy < 1 year;
intracranial hemorrhage or major surgery within 30 days
of the procedure; uncontrolled arterial hypertension or
coagulopathy; contraindications to heparin or antiplate-
let therapy; a lack of percutaneous vascular access.
Pretreatment evaluation
The human group that worked as a team in all the pro-
cedures was formed by neurologists and interventional
radiologists, with whom an anesthetist collaborated. The
team performs a joint assessment of each case to deter-
mine the most appropriate treatment for each patient.
Pretreatment evaluation included an assessment of the
degree of stenosis using noninvasive imaging, a neuro-
logical assessment (NIH stroke scale), laboratory results,
and a 12-lead ECG. Any changes in medication were
agreed by the medical team.
All patients agreed to, and provided, written (signed)
informed consent. Patients received antiplatelet therapywith daily oral entericoated aspirin (100 mg per day) and
clopidogrel (75 mg per day) at least 3 days prior to the
procedure. Patients using long-term anticoagulation had
their treatment converted to heparin.
Procedure protocol
CAS procedures were performed by 2 interventional
radiologists, one with more than 30 years of experience
in endovascular techniques. In most patients, and when
practicable in the hospital setting, endovascular treat-
ments were performed within the first 2 weeks of
becoming symptomatic (76,4%), except in those cases
where there was a high risk of bleeding and hyperperfu-
sion syndrome (Kernan et al., 2014; Furie et al., 2011;
Sacco et al., 2006).
The right common femoral artery (CFA) is the pre-
ferred access for CAS. The left CFA and the brachial
artery were alternative accesses if the right CFA was not
possible. A 6 French sheath and a 0.035″ hydrophilic
wire (Terumo Europe) is advanced into the aorta under
direct fluoroscopy. A multiside-hole pigtail catheher
(Cook Medical, Bloomington, IN) was placed over the
guide wire and positioned in the aortic arch. An aorto-
gram was obtained with 30 cm3 of contrast at 15 ml/s
(Ioversol 320 mg/ml).
Catheter selection for CCA was chosen depending on
the aortic arch anatomy. The used catheter was a 5 Fr
Vertebral (Terumo, Europe). Selection of great vessels in
the setting of Type III arch typically required a reverse
curve catheter type Simmons II (Terumo Europe) or a
brachial approach when femoral access was not possible.
A carotid angiography was performed in AP, lateral, and
intra-cerebral (Towne and lateral views).
A 260 cm safety “J” guidewire was advanced to the
ECA, and a 6 Fr - 90 cm guiding catheter (Flexor - Cook
Medical, Bloomington, IN) was then placed in the CCA.
Anticoagulation was infused with a bolus of 80 IU/kg of
UFH. In scenarios of appropriate anatomic conditions
an embolic protection device (EPD; Accunet, Abbott
Vascular, Santa Clara, CA) was deployed distally (4.5–
6.5 mm). The authors tried to use EPD in all patients re-
gardless of the type of plaque. A self-expanding carotid
stent system (Acculink, Abbott Vascular, Santa Clara,
CA) was then placed across the stenosis.
Predilation of the stenosis after the placement of the
EPD and before stent deployment was controversial. The
IR’s performed predilatation when the stent cannot be
safely advanced. If predilation was desired, a 5 × 20 mm
diameter balloon should suffice and atropine was given
prophylactically if bradycardia ensues (procedure was
perform always with an anesthesiologist).
A repeat arteriogram was performed. Any residual
stenosis exceeding 30% was treated with a 5 × 20 mm
diameter balloon angioplasty and atropine was given
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(75 mg for 4 to 6 weeks), and aspirin (100 mg; used
indefinitely),
Data collection and follow-up
We retrospectively collected all clinical, angiographic,
and procedural data. A neurological specialist performed
the clinical follow-ups, with carotid ultrasound at 1, 3, 6,
and 12 months after the intervention, and annually
thereafter. If there was any alteration in carotid ultra-
sound (PSV > 200 or ICA/CCA ratio > 3), a selective
angiogram was performed.
All patients were treated with BMT. We made strict
control of blood pressure to keep levels < 120/80, LDL
cholesterol to keep levels < 70 and blood sugar control
to keep levels of HbA1c < 7%. We make patients aware
of a healthy lifestyle attempting to be physically active,
non-smokers and trying to maintain a healthy body
weight.
Definitions
Patients were considered symptomatic if they presented
with ipsilateral amaurosis fugax, transient ischemic at-
tack (TIA), or ischemic stroke within 4 months of the
procedure. Stroke was defined as a neurological deficit
of cerebrovascular cause that persists beyond 24 h, or a
new cerebrovascular lesion in neuroimaging. TIA was
defined as a focal neurologic deficit that resolves com-
pletely within 24 h. A MI component was defined on the
basis of elevated myocardial enzymes plus either symp-
toms or electrocardiographic evidence of an event.
Technical success was defined as restoration of cerebral
flow through the lesion, with a > 20% improvement in
stenosis and a residual stenosis of < 50%. Major compli-
cations included death, stroke or MI. Minor complica-
tions were defined as all those that do not require any
intervention. Global complications were defined as the
sum of major and minor complications. Restenosis was
classified when the intra-stent stenosis was greater than
50% (Higashida et al., 2009). Efficacy was defined as the
absence of stroke during follow-up. Neurological death
was defined as that caused by stroke or associated with
procedural complications. Vascular death was defined as
that caused by MI or peripheral artery disease (PAD).
Aims and statistical analysis
The primary aim of the study was to analyze stroke, MI,
or death during the periprocedural period (30 days after
treatment), or any stroke-event over a 15-year follow-up.
We also evaluated the long-term behavior of the
implanted carotid stents in terms of patency rate and
the need for reintervention. Our secondary aim was to
identify predictive risk factors for 30-day complications,
long-term neurological complications, and ISR.Statistical analyses were with the SPSS software (Re-
leased 2012; IBM SPSS Statistics for Macintosh; Version
21.0. Armonk, NY: IBM Corp). Normality was tested
using the Kolmogorov-Smirnoff test. Quantitative vari-
ables were expressed as mean values with standard devi-
ations. Qualitative data were expressed as the total
number of events with percentages. Continuous vari-
ables were analyzed using either the Student’s t-test or
the Mann-Whitney U test. The Chi-squared and Fisher’s
exact tests, or likelihood ratios, were used for categorical
variables. Survival curves were calculated using the
Kaplan-Meier method and were compared with the
log-rank test. All tests were considered statistically
significant if the p value was less than 0.05.Results
From January 2001 through December 2015, a total of
344 patients with a median age of 70.79 years (range
44–86) were treated with CAS. The procedure was more
common among men than women, with 86% of patients
male. All but 35 (10.2%) patients were symptomatic.
Demographics, risk factors, and patient morbidities are
listed in Table 1. Hypertension, dyslipidemia, and smok-
ing were the most potent, prevalent, and treatable risk
factors for stroke.
The carotid stent deployed was the Acculink with no
procedures aborted before insertion of the stent. Protec-
tion devices were used for 60.2% of patients. Post-stent
balloon dilatation was performed in 73.8% of patients,
with predilatation necessary for 20/344 arteries (5.8%).
Technical success was achieved in 335 of the 344
arteries (97.4%) treated. Although it was possible to pass
a wire through the stenosis in 9 patients, complete stent
expansion was not achieved for this group.
The primary composite end point was 2.3% (Table 2).
Strokes occurred in 8 patients, with the only death
related to severe bleeding in the context of a hyperperfu-
sion syndrome. None of the stroke events were the
result of an acute stent thrombosis. There were no
patients with MI.
We undertook exploratory analyses of the composite
outcome of stroke, death, or procedural myocardial in-
farction. These analyses suggested that use of an EPD
was protective against major complications (Table 3). In
addition, EPD-use led to a reduction in major complica-
tions, falling from 5,1% without the use of EPDs to 0.5%
with EPDs (p = 0.005).
For long-term analysis, patients were followed for a
median of 50 months (range 0-155 months). A total
of 50 patients were lost to follow-up (Table 4), with
long-term follow-up achieved in 294 patients (85.5%).
Fifty-six (16.3%) patients died within this period,
including 4 stroke-related deaths, and 52 non-lesion
Table 1 Baseline characteristics of patients
Vascular risk factors Men (n = 296) Women (n = 48) Total (n = 344) p
Hypertension 69,6% 70,8% 69,8% 0,862 X2
PAD 27,7% 16,7% 26,2% 0,107 x2
Previous TIA 7,1% 4,2% 6,7% 0,754 F
Previous Stroke 10,1% 8,3% 9,9% > 0,999 F
Dyslipidemia 59,1% 64,6% 59,9% 0,474 x2
Smoking 41,6% 10,4% 37,2% < 0,001 x2
Alcohol 3,4% 0,0% 2,9% 0,368 F
DM 33,8% 25,0% 32,6% 0,228 x2
Obesity 18,9% 29,2% 20,3% 0,102x2
Arrhythmias 9,1% 18,8% 10,5% 0,043 x2
Ischemic heart disease 26,0% 14,6% 24,4% 0,087 x2
Cervical radiotherapy 2,4% 2,1% 2,3% > 0,999 F
X2: Chi-squared test; F: Fisher’s exact tests
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from intraparenchymal hemorrhage and two from is-
chemic stroke, one ipsilateral to the treated carotid
artery and the other, contralateral to the treated ca-
rotid artery. Among the non-neurological deaths,
there were 5 cases of vascular death: 3 cases due to
chronic ischemia of the lower extremities, and 2 due
to acute myocardial infarction (Fig 1).
During the follow-up period, 8 strokes and 3 TIAs
were diagnosed (3.2%). The majority of the strokes
(75%) were contralateral to the treated carotid artery
and most were ischemic. We did not identify any pre-
dictive risk factors or any procedural characteristics
for ipsilateral neurological complication.
ISR was assessed in 4.4% of the patients and
remained asymptomatic in all but 2 patients (0.6%).
All patients with restenosis underwent revasculariza-
tion with balloon angioplasty. No stent fracture was
observed. Pre-stent angioplasty was significantly asso-
ciated with the incidence of ISR (Table 5). Risk
factors were neither related to neurological complica-
tions nor ISR. Further, there were significant differ-
ences between the degree of restenosis and the time
of its appearance: the greater the degree of restenosis,
the shorter the post-procedure time period (r = − 0.426;
p = 0.038). We found no association between restenosis





Fatal Stroke (death) 1 0,3%Discussion
Stroke is a major cause of mortality and morbidity in in-
dustrialized countries. These data, combined with an
ever-increasing life expectancy, necessitates that we con-
duct more detailed analyses of whether carotid revascular-
ization is a safe and effective treatment with which to
prevent stroke.
In our series, the 30-day outcomes after CAS show
that carotid stenting is an effective treatment in prevent-
ing future vascular events, with a low incidence of peri-
procedural complications: 2.3% for disabling stroke,
death, or MI. Previous systematic reviews of nonrando-
mized cases series (Kastrup et al., 2003), as well as sev-
eral studies (Castriota et al., 2002; Cremonesi et al.,
2003; Garg et al., 2009; Giri et al., 2015), have shown
that EPD-use appears to reduce the incidence of new
ischemic lesions. However, various reports have also crit-
icized the use of EPDs in CAS as these devices must
pass through the arterial stenosis, which might itself
provoke complications (Reimers et al., 2004; Wu et al.,
2011) and a greater incidence of microemboli (El-Koussy
et al., 2007). Nevertheless, the results of our series show
a decreased rate of major complications when EPDs are
used (p = 0.005), which therefore classifies these devices
as protective against stroke.
To our knowledge, our study comprises the largest
patient cohort, with the longest national follow-up to
compare stroke prevention in patients treated by the
same surgical team. In our series, stenting was per-
formed electively as an alternative to endarterectomy.
This is because the committee composed by neurologist,
radiologist, and interventional radiologist (vascular sur-
geons refused to participate) decided, more than 15 years
ago to send patients directly to CAS, depending on the
poor results of the surgery department. Thus, our indi-
cations were not limited to patients at a high surgical
Table 3 The influence of procedural characteristics on peri-procedural complications
Variable Major complicatons Minor complications
n % p n % p
Ulcer No 8 3,3% 0,111F No 96 39,7% 0,109x2
Yes 0 0,0% Yes 50 49,0%
Pre-stent angioplasty No 8 2,5% > 0,999F No 131 40,4% 0,002x2
Yes 0 0,0% Yes 15 75,0%
EPD No 7 5,1% 0,005X2 No 46 33,6% 0,007x2
Yes 1 0,5% Yes 100 48,3%
Post-stent angioplasty No 2 2,2% > 0,999F No 34 37,8% 0,297x2
Yes 6 2,4% Yes 112 44,1%
X2: Chi-squared test; F: Fisher’s exact tests
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tion was low, and similar to data from surgical registries
with more stringent inclusion criteria (North American
Symptomatic Carotid Endoarterectomy Trial Collaboration,
1991; Executive Committee for the Asymptomatic Carotid
Atherosclerosis Study, 1995).
The CREST study showed no significant differences
between stent and endarterectomy in terms of the risk
of stroke or death over its 10-year follow-up. Indeed, the
higher risk of stroke reported for CAS can be attributed
to the periprocedural differences between the two
groups (Brott et al., 2016; Brott et al., 2010), and the
infrequent use of EPDs (El-Koussy et al., 2007). Other
randomized trials comparing both techniques have been
reported, and showed no significant differences after
long-term follow-up (Bonati et al., 2015; Gurm et al.,
2008; Mas et al., 2008).
Our data appears to indicate that CAS is preventive
against ipsilateral stroke with a low long-term risk of
severe stroke The recurrence rate in our series of 3.2%
primarily involved strokes contralateral (75%) to the
treated carotid artery, and most were ischemic. This
finding has also been reported in previous related studies
in which no significant difference in cumulative rates of
fatal or disabling stroke were found for stenting vs. end-
arterectomy (Bonati et al., 2015; Mas et al., 2008). It is
interesting to note that our observed stroke rate of
3.2% is (fairly) consistent with, and even lower than
the 8.5% reported in the ECST at 3 years (European
Carotid Surgery Trial, 1998), and the 13% rate of the
NASCET (North American Symptomatic CarotidTable 4 Follow-up period
Follow-up (months) n % Average SD Median (IQR)
Keep in follow-up 238 69,19% 56,40 36,30 48,90 (59,50)
Loss to follow-up 50 14,53% 34,08 29,28 30,04 (41,50)
Neurological death 4 1,16% 10,36 10,69 8,14 (19,25)
No neurological death 52 15,12% 38,33 31,28 35,53 (44,50)Endoarterectomy Trial Collaboration, 1991). However,
our patient population was closely monitored in terms of
risk factors, which may have lowered our rate of complica-
tion. Regarding risk factors, Donato et al. (de Donato
et al., 2008) and Brooks et al. (Brooks et al., 2014) found
that being symptomatic at the time of enrollment and
intervention was a good predictor of early and late neuro-
logical complication. We failed to find any risk factor
associated with late neurological complications, although
this may be related to our low recurrence rate.
Prevention of ipsilateral stroke is the ultimate goal of
any treatment for carotid stenosis. However, durability,
defined as patency determined by Doppler ultrasound,
may also serve as a useful definition of therapeutic util-
ity. Our analysis of long-term outcomes showed that the
long-term rate of restenosis after stenting was low
(4.4%), and comparable, or even lower, than those
achieved with CEA. However, direct comparisons are
complicated by the criteria used to make a diagnosis in
Doppler sonography. Of the restenosis cases, only 2
(0.6%) were symptomatic. We found no association
between restenosis and recurrent events, but pre-stent
angioplasty was significantly associated with the inci-
dence of ISR. This is difficult to interpret given the small
number of recurrent events, pre-stent angioplasty, and
restenoses seen in our study. A certain amount of con-
troversy surrounds the issue of long-term rates of
restenosis after stenting vs. endarterectomy. Some
trials (Bonati et al., 2015; Brott et al., 2016; Mas
et al., 2008) have demonstrated no differences when
comparing both techniques. For example, 5-year risks
of 10.8% vs. 8.6%, 3-year risks of 3.3% vs. 2.8%, and
2-year risks of 6.0% vs. 6.3%, for stenting vs. endarter-
ectomy, have been reported, respectively. In contrast,
the CAVATAS (Bonati et al., 2009) and SPACE trials
(Eckstein et al., 2008) reported higher rates of resten-
osis 2 years after treatment in the stenting group vs.
endarterectomy group (10.7% vs. 4.6%). Consequently,
further studies are needed to compare the rate of
Fig. 1 Survival curves for vascular and non vascular deaths
Mayoral Campos et al. CVIR Endovascular  (2018) 1:3 Page 6 of 8restenosis and to investigate the association between
restenosis and recurrent stroke.
The current study has several limitations. The main
limitation was its small sample size and retrospective
design. Moreover, results obtained in this study were
compared with the literature, as it was not possible to
undertake a randomized comparison of CAS versus
CEA. Further, the efficacy of the EPDs could not be eval-
uated throughout the entirety of this study as these
devices were not available until 2005.
Conclusion
The long-term follow-up results of our study validate
CAS as a safe and durable procedure with which to pre-
vent ipsilateral stroke. Our data also suggest that CAS isTable 5 The influence of procedural characteristics on
restenosis
Proceure Reestenosis n % p
Peri-procedural complications No 142 6,8% 0,866x2
Yes 152 7,2%
Pre-stent angioplasty No 322 5,6% 0,001LR
Yes 20 25,0%
Post-stent angioplasty No 77 9,1% 0,353LR
Yes 254 6,3%
X2: Chi-squared test; LR: likelihood ratioseffective in terms of long-term functional outcome and
risk of fatal or disabling stroke. Post CAS restenosis was
infrequent, and, in the majority of cases, asymptomatic.
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